Den Europæiske Union - tysk - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antithrombotische mittel - prävention venöser thromboembolien (vte) bei erwachsenen patienten, die sich einer hüft- oder kniegelenksersatzoperation unterziehen. behandlung von tiefen venenthrombosen (tvt) und lungenembolie (pe) und prävention von wiederkehrenden dvt und pe bei erwachsenen. (see section 4. 4 for haemodynamically unstable pe patients. behandlung von tiefen venenthrombosen (tvt) und lungenembolie (pe) und prävention von wiederkehrenden dvt und pe bei erwachsenen. (see section 4. 4 für hämodynamisch instabile pe-patienten). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandlung von tiefen venenthrombosen (tvt) und lungenembolie (pe) und prävention von wiederkehrenden dvt und pe bei erwachsenen. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 und 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandlung von tiefen venenthrombosen (tvt) und lungenembolie (pe) und prävention von wiederkehrenden dvt und pe bei erwachsenen. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Den Europæiske Union - tysk - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotische mittel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Schweiz - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - perindoprilum, amlodipinum - tabletten - perindoprili tosilas 5 mg corresp. perindoprilum 3.408 mg, amlodipinum 5.0 mg ut amlodipini besilas, natrii hydrogenocarbonas, povidonum k 30, isomaltum 86.6 mg, cellulosum microcristallinum, carboxymethylamylum natricum, magnesii stearas, pro compresso corresp. natrium 0.669 mg. - hypertonie, stabile koronare herzkrankheit - synthetika

Schweiz - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - perindoprilum, amlodipinum - tabletten - perindoprili tosilas 5 mg corresp. perindoprilum 3.408 mg, amlodipinum 10.00 mg ut amlodipini besilas, natrii hydrogenocarbonas, povidonum k 30, isomaltum 86.6 mg, cellulosum microcristallinum, carboxymethylamylum natricum, magnesii stearas, pro compresso corresp. natrium 0.669 mg. - hypertonie, stabile koronare herzkrankheit - synthetika

Schweiz - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - perindoprilum, amlodipinum - tabletten - perindoprili tosilas 10.0 mg corresp. perindoprilum 6.815 mg, amlodipinum 5.0 mg ut amlodipini besilas, natrii hydrogenocarbonas, povidonum k 30, isomaltum 173.2 mg, cellulosum microcristallinum, carboxymethylamylum natricum, magnesii stearas, pro compresso corresp. natrium 1.338 mg. - hypertonie, stabile koronare herzkrankheit - synthetika

Schweiz - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - perindoprilum, amlodipinum - tabletten - perindoprili tosilas 10.0 mg corresp. perindoprilum 6.815 mg, amlodipinum 10.0 mg ut amlodipini besilas, natrii hydrogenocarbonas, povidonum k 30, isomaltum 173.2 mg, cellulosum microcristallinum, carboxymethylamylum natricum, magnesii stearas, pro compresso corresp. natrium 1.338 mg. - hypertonie, stabile koronare herzkrankheit - synthetika

Schweiz - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

ge healthcare ag - regadenosonum - injektionslösung - regadenosonum 400 µg, dinatrii phosphas, natrii dihydrogenophosphas, propylenglycolum 750 mg, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 5 ml corresp. natrium 19 mg. - koronarer vasodilatator der anstelle von stressübungen für myokardperfusionsaufnahmen mit radionukliden angewendet wird. - synthetika

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - acetylsalicylsäure (ph.eur.) - tablette - teil 1 - tablette; acetylsalicylsäure (ph.eur.) (00002) 50 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

zentiva pharma gmbh (8075753) - iloprost - lösung für einen vernebler - 20 µg/ml - teil 1 - lösung für einen vernebler; iloprost (22261) 0,02 milligramm

Østrig - tysk - AGES (Agentur für Gesundheit und Ernährungssicherheit)

sintetica gmbh - ropivacain hydrochlorid -